200 results on '"Parant F"'
Search Results
2. Profil cytokinique des patientes porteuses d’implant Essure : vers une signature moléculaire
3. Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
4. Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
5. Pharmacocinétique des antirétroviraux au cours de la grossesse : bilan d'un laboratoire de pharmacologie sur la période 2015-2021
6. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome
7. MDP Derivatives and Resistance to Bacterial Infections in Mice
8. Enhancement of Nonspecific Immunity to Klebsiella Pneumoniae Infection by a Synthetic Immunoadjuvant (N-Acetylmuramyl-L-Alanyl-D-Isoglutamine) and Several Analogs
9. Enhancement of the Neonate's Nonspecific Immunity to Klebsiella Infection by Muramyl Dipeptide, a Synthetic Immunoadjuvant
10. Enhancement of Certain Biological Activities of Muramyl Dipeptide Derivatives after Conjugation to a Multi-poly(DL-alanine)--poly(L-lysine) Carrier
11. Biological Study of a Nontoxic, Water-Soluble Immunoadjuvant from Mycobacterial Cell Walls
12. Routine use of a one minute trehalase and maltase test for the identification of Candida glabrata in four laboratories
13. Métabolites urinaires de la nicotine : évaluation des immunodosages EIA « Cotinine » Microgenics et Immulite 2000 « Métabolites de la nicotine » DPC en comparaison à la colorimétrie
14. 378 Toxic metal elements release from essure device in symptomatic patients: A prospective comparative cohort study
15. MDP Derivatives and Resistance to Bacterial Infections in Mice
16. Hybridization by Deoxycholate Treatment or by Biological Degradation of Bacterial Endotoxins Extracted from Smooth and Rough Strains
17. Enhancement of Nonspecific Immunity to Bacterial Infection by Cord Factor (6,6'-Trehalose Dimycolate)
18. Effect of Indomethacin on Increased Resistance to Bacterial Infection and on Febrile Responses Induced by Muramyl Dipeptide
19. The effect of an acute inflammatory process on the resistance to infections in mice
20. Nonspecific Effects of LPS on Bacterial Infections
21. An automated assay for the determination of serum ceruloplasmin ferroxidase activity
22. In Vitro Fixation and Degradation of Radioactive Endotoxin by the RES of BCG-Treated Mice
23. Les effets indésirables neuropsychiatriques sous dolutégravir sont-ils corrélés au niveau d’exposition sérique ?
24. BU-28 - Nouvelle forme galénique du posaconazole (Noxafil®) – Expérience d’un laboratoire hospitalier de pharmacologie
25. Switching from cyclosporine to tacrolimus in renal transplant recipients: impact on mycophenolic acid exposure
26. Dépistage urinaire de la 6-monoacétylmorphine par méthode immunoenzymatique CEDIA : évaluation et comparaison à la GC-MS
27. Immunopharmacologic Approaches to Bacterial Infection
28. Dosage de la carbamazépine (Tégrétol®) sur analyseurs Dimension RxL / Xpand (Dade Behring) : préférez les réactifs 'EMIT' (en canal ouvert) aux réactifs 'PETINIA' !
29. L’intensité de l’exposition à l’acide mycophénolique est-elle un facteur de risque d’infection à BK virus ?
30. LSD Screening in Urine Performed by CEDIA(R) LSD Assay: Positive Interference with Sertraline
31. Dosage du mycophénolate par méthode enzymatique (inhibition de l’IMPDH) : comparaison avec une technique séparative et adaptation sur analyseur Cobas C 111
32. P.360 Hépatite C de génotype 1 : escalade de dose de ribavirine chez les malades non répondeurs et suivi pharmacologique et virologique
33. P.362 Dosages sanguins de ribavirine au cours du traitement de l’hépatite C chronique : quel intérêt ?
34. SYNDROME PHALLOÏDIEN: QUELLE EST LA PLACE DU DOSAGE DES α-ET γ-AMANITINES PAR ELISA (BÜHLMANN)? Résultats préliminaires
35. Delayed toxicity following acute ingestion of valpromide
36. Identification of Candida glabrata by a 30-Second Trehalase Test
37. Long-term urinary copper excretion and exchangeable copper in children with Wilson disease on chelation therapy: a pilot study.
38. Performance of relative exchangeable copper for the diagnosis of Wilson disease in children.
39. Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides
40. Induction of biologically active antibodies by βhCG conjugated to a synthetic peptide carrier and adminisetred with MDP[THR]GDP in a clinically suitable formulation
41. Nicotine metabolites in urine: assessment of EIA “Cotinine” Microgenics and Immulite 2000 “Nicotine metabolite” DPC in comparison with colorimetric method.
42. Enhancement of Nonspecific Immunity to Bacterial Infection by Cord Factor (6,6′MTrehalose Dimycolate).
43. Identification of Candida glabrataby a 30-Second Trehalase Test
44. Failure of endotoxin to increase nonspecific resistance to infection of lipopolysaccharide low-responder mice
45. Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative
46. Dissociation between muramyl dipeptide-induced fever and changes in plasma metal levels
47. Inheritance of lipopolysaccharide-enhanced nonspecific resistance to infection and of susceptibility to endotoxic shock in lipopolysaccharide low-responder mice
48. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity
49. Nonspecific immunostimulant activities of synthetic trehalose-6,6'-diesters (lower homologs of cord factor)
50. Biological activities of endotoxins detoxified by alkylation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.